Kelun Pharmaceutical and its subsidiaries have multiple products tentatively selected in the 12th round of national centralized drug procurement. The company announced on August 2 that it participated in the bidding organized by the National Drug Joint Procurement Office on July 31, with tentatively selected products including sacubitril valsartan sodium tablets, fat emulsion injection, compound amino acid injection, enzalutamide soft capsules, and trazodone hydrochloride tablets. In the first quarter of 2026, Kelun Pharmaceutical achieved revenue of 4.259 billion yuan and net profit attributable to the parent of 454 million yuan.
Sichuan Kelun Pharmaceutical Co LtdMultiple products tentatively selected in national procurement, likely boosting sales.